Display options
Cite
Delgado J, Zienowicz M, van Hennik PB, et al. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. Oncologist. 2021;26(11):983-987doi: 10.1002/onco.13892.
Delgado, J., Zienowicz, M., van Hennik, P. B., Moreau, A., Gisselbrecht, C., Enzmann, H., & Pignatti, F. (2021). EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. The oncologist, 26(11), 983-987. https://doi.org/10.1002/onco.13892
Delgado, Julio, et al. "EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma." The oncologist vol. 26,11 (2021): 983-987. doi: https://doi.org/10.1002/onco.13892
Delgado J, Zienowicz M, van Hennik PB, Moreau A, Gisselbrecht C, Enzmann H, Pignatti F. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. Oncologist. 2021 Nov;26(11):983-987. doi: 10.1002/onco.13892. Epub 2021 Jul 19. PMID: 34213061; PMCID: PMC8571773.
Copy Download .nbib Format: NLM
Share it on

Oncologist. 2021 Nov;26(11):983-987. doi: 10.1002/onco.13892. Epub 2021 Jul 19.

EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.

The oncologist

Julio Delgado, Malgorzata Zienowicz, Paula Boudewina van Hennik, Alexandre Moreau, Christian Gisselbrecht, Harald Enzmann, Francesco Pignatti

Affiliations

  1. Oncology and Hematology Office, European Medicines Agency, Amsterdam, The Netherlands.
  2. Department of Hematology, Hospital Clinic, Barcelona, Spain.
  3. Committe for Medicinal Products for Human Use, European Medicines Agency, Amsterdam, The Netherlands.
  4. College ter Beoordeling van Geneesmiddelen, Utrecht, The Netherlands.
  5. Agence Nationale de Securite du Medicament et des Produits de Sante, Saint-Denis, France.
  6. Hopital Saint Louis, Paris, France.
  7. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.

PMID: 34213061 PMCID: PMC8571773 DOI: 10.1002/onco.13892

Abstract

Isatuximab is a monoclonal antibody that binds to the human CD38 antigen. On May 30, 2020, a marketing authorization valid through the European Union (EU) was issued for isatuximab in combination with pomalidomide and dexamethasone (IsaPd) for the treatment of adult patients with relapsed and refractory (RR) multiple myeloma (MM). The recommended dose of isatuximab was 10 mg/kg, administered intravenously weekly at cycle 1 and then biweekly in subsequent 28-day cycles. Isatuximab was evaluated in a phase III, open-label, multicenter, randomized trial that randomly allocated IsaPd versus pomalidomide plus dexamethasone (Pd) to adult patients with RR MM. The primary endpoint of the trial was progression-free survival, as assessed by an independent review committee, which was superior for the IsaPd arm (hazard ratio, 0.596; 95% confidence interval, 0.436-0.814; p = .001) compared with the Pd arm. Treatment with IsaPd led to higher incidences of treatment-related adverse events (AEs), grade ≥ 3 AEs, and serious AEs compared with Pd treatment. Most frequently observed AEs that occurred more often in the IsaPd arm were infusion-related reactions, infections, respiratory AEs, neutropenia (including neutropenic complications), and thrombocytopenia. The aim of this article is to summarize the scientific review of the application leading to regulatory approval in the EU. IMPLICATIONS FOR PRACTICE: Isatuximab was approved in the European Union, in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have already received therapy but whose disease did not respond or relapsed afterward. The addition of isatuximab resulted in a clinically meaningful and significant prolongation of the time from treatment initiation to further disease relapse or patient's death. The safety profile was considered acceptable, and the benefit-risk ratio was determined to be positive.

© 2021 AlphaMed Press.

Keywords: Dexamethasone; EMA • Anti-CD38 antibody; Isatuximab; Multiple myeloma; Pomalidomide

References

  1. Leukemia. 2020 Dec;34(12):3298-3309 - PubMed
  2. Am Soc Clin Oncol Educ Book. 2017;37:575-585 - PubMed
  3. N Engl J Med. 2007 Nov 22;357(21):2123-32 - PubMed
  4. Blood Cancer J. 2019 Mar 29;9(4):41 - PubMed
  5. Clin Cancer Res. 2014 Sep 1;20(17):4574-83 - PubMed
  6. N Engl J Med. 2016 Apr 28;374(17):1621-34 - PubMed
  7. Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61 - PubMed
  8. Lancet. 2019 Dec 7;394(10214):2096-2107 - PubMed
  9. Eur J Haematol. 2018 Apr 20;: - PubMed
  10. N Engl J Med. 2015 Sep 24;373(13):1207-19 - PubMed
  11. Blood. 2010 Nov 11;116(19):3724-34 - PubMed
  12. Leukemia. 2016 Feb;30(2):399-408 - PubMed
  13. Lancet Oncol. 2014 Oct;15(11):1195-206 - PubMed
  14. Clin Cancer Res. 2019 May 15;25(10):3176-3187 - PubMed
  15. Lancet Oncol. 2013 Oct;14(11):1055-1066 - PubMed
  16. N Engl J Med. 2015 Aug 13;373(7):621-31 - PubMed
  17. Blood. 2019 Jul 11;134(2):123-133 - PubMed
  18. N Engl J Med. 2018 Nov 8;379(19):1811-1822 - PubMed
  19. N Engl J Med. 2015 Jan 8;372(2):142-52 - PubMed

Publication Types